MT921

DRUG3 trials

Sponsors

Medy-Tox

Conditions

Healthy VolunteersSubmental Fat

Phase 1

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

CompletedNCT03905291

Medy-ToxHealthy Volunteers

Start: 2018-07-31End: 2018-12-26Updated: 2020-08-25

Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

CompletedNCT04144049

Medy-ToxSubmental Fat

Start: 2019-09-10End: 2020-04-23Updated: 2020-07-29

Phase 3

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

CompletedNCT05195112

Medy-ToxSubmental Fat

Start: 2021-12-24End: 2023-02-18Updated: 2023-02-23